THIS FRIDAY: Session IV at the Advanced Heart Failure Summit: Case Dilemmas in Transplant & LVAD. Real patients, contested calls — LVAD or transplant? Commit to recovery or escalate? Interactive discussions with faculty from @ColumbiaMed@WeillCornell@MountSinai@BrighamWomens@NYPHospital
📅 Fri June 26 | 4:15 PM ET
📍 Myrna Daniels Heart Center, NYP | Also virtual
Register: https://t.co/db2GzKy2XJ
#Cardiology #HeartFailure
Thank you @TheJHLT for highlighting our work. We found that dd-cfDNA was a stronger marker of active molecular ABMR than DSA, while MMDx identified rejection missed by conventional histology. Together, they may improve the detection of clinically meaningful graft injury after HT
Increasing sensitivity: MMDx detected molecular ABMR more often than histology. #ddcfDNA outperformed DSA for detecting molecular ABMR, with no added value in combination.
DSA ≠ tissue damage. dd-cfDNA + MMDx capture active antibody-mediated injury.
#HeartTransplant#ABMR #ddcfDNA #MMDx
🔗: https://t.co/nDMcsDQaNn
Histology says ‘benign,’ but molecular diagnostics tell another story: Quilty lesions show elevated dd-cfDNA & TCMR transcripts on MMDx. This paper highlights the need for molecular surveillance in #HeartTransplant care. 🫀
🔗: https://t.co/Vs5JxXDqvj
🔬 Quilty lesions have long occupied an uncertain space in transplant pathology
In our study, Quilty was independently associated with higher dd-cfDNA & GEP scores, a MMDx-TCMR signature, & persistent dd-cfDNA elevation
In the accompanying editorial, colleagues from pathology offer a similar interpretation: Quilty is repositioned as a hypothesis-generating marker at the interface of 🔬 histology, transcriptomics, and circulating biomarkers
A reminder that immune activity is not always fully captured by morphology alone
@NirUrielMD@gtsayer@Columbia
🔗 Link to our publication https://t.co/87p1bmQK34
Considerations for the net prolongation of life with a durable LVAD first strategy in younger pts in need of Adv HF therapies
Now in @JACCJournals#JACCHF
Link: https://t.co/ONXauJBdnX
Mi compi Jesús❤️#cardiólogo de #LaPaz , sonrisa eterna y trabajador incansable.
Desaparecido en Iryo #Ave#Tren🚂 😢
Nos tiene sin noticias desde ayer😢.
Si los compañeros de vagón, sanitarios,…nos ayudan o aportan información , se agradece todo 🫂
📣 Scholarship Opportunity for Trainees!
We’re offering 3 scholarship awards to support WiTMCS trainee members to attend @ISHLT’s 46th Annual Meeting & Scientific Sessions in Toronto, April 2026 🌍
Apply here:👉 https://t.co/b6HMYta2UX
✅ Eligibility: WiTMCS trainee members only
@TheJHLT@MoAbdullahCTS 🫀In Spain, donation after MAiD (Maastricht type V controlled asystole) began in 2022 after the Organización Nacional de Trasplantes (ONT) developed a specific protocol. Since then, 5 heart transplants were performed in 2022, 5 in 2023, and 13 in 2024.
@contrastado Barcelona irreconocible un autentico estercolero!!! Una ciudad emblematica, referente mundial hecha un desastre!!!!!! No se puede caminar x debajo d Diagonal… asqueroso
In this CSWG analysis, patients supported with Impella 5.5 beyond the FDA-approved duration of 14 days had high rates of favorable outcomes, especially as bridge to #heart replacement therapies. @manreetkanwar @NirUrielMD@NavinKapur4 🫀
🔗: https://t.co/NvNxqxr7qk
MARÍA CORINA, NOBEL PEACE PRIZE 2025
The 2025 Nobel Peace Prize awarded to María Corina Machado does not only honor a brave, intelligent, and steadfast woman who has faced tyranny for a quarter of a century. It also honors a nation that chose to resist without weapons, to prevail through hope and not hatred, and to believe in her and in her strategy without fear.
Through these long and harrowing years, María Corina has confronted the forces of a thoroughly criminal regime, “opposition figures” and “pollsters” tamed by it, complicit businessmen, and cowardly bureaucrats across countless countries.
She has spent eleven years unable to leave our country, unable to embrace her children freely or celebrate their academic achievements—like the children and grandchildren of millions forced to flee. And she has never complained. On the contrary, she made the reunification of Venezuelan families in Venezuela her banner, understanding that nothing matters more to our people than being together again.
Congratulations, my dear friend.
Deserved for so many reasons.
Just for so many more.
El Final is closer than ever.
One step further🪜Subclinical injury isn’t benign. 1/3 of “negative” biopsies with ↑ dd-cfDNA revealed rejection on MMDx. Moving toward a new era of molecular surveillance. @CathMoellerMD@Daniel_OrenMD@NirUrielMD@Columbia
What are the clinical implications of +ddcfDNA in HTx pts with negative EMB?
We observed a significantly higher risk of adverse clinical events (mortality/graft dysfunction) in this specific cohort
Now in @CircHF https://t.co/4GkPShDIa0
Excited for the 2025 Heart Failure Research Symposium! Looking forward to listen to the key note speaker and winner of the research competition by Dr. Martin Leon on the journey of structural heart!
There is still time to join us this afternoon! Sign up below
Prospective study: #ddcfDNA showed superior performance in predicting rejection by MMDx (AUC 0.89) with an optimal cut-off value of 0.26% than by histology (AUC 0.64). Helps clinicians refine testing & management for patients with elevated dd-cfDNA
🔗: https://t.co/9WHMHuAnzY
Our @CU_Cardiology experience with letermovir prophy for mod/high risk CMV post-OHT, a promising new therapy to avoid the typical leukopenia seen with valcyte
Link to article now in @JCardFail
https://t.co/nb6YiKCV9o
Molecular microscope in combination with cfDNA diagnosed more rejection than histology - are we on the precipice of new gold standard in rejection detection, learn more in our new paper in @TheJHLT@ISHLT@CUMCHeartSource@CU_Cardiology
https://t.co/OZbalcczvV